Skip to main content
SpringerLink
Log in

Combination of interferons and cytostatic drugs for treatment of advanced colorectal cancer

  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Summary

Three phase I/II trials were performed in patients with metastatic colorectal cancer using immunochemotherapy — a combination of recombinant interferonβ undγ with low doses of cytostatic drugs. The third regimen, consisting of a cytostatic component containing 5-fluorouracil plus carboplatin plus mitomycin C besides the interferons, produced a high remission rate of 47%: 14/30 patients responded. The tolerability of this protocol was good and it could be administered on an out-patient basis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ajani JA, Rios AA, Ende K, Abruzzese JL, Edwards C, Faintuch EJ, Sacks S, Gutterman JU, Levin B (1989) Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. J Biol Response Mod 8:140–146

    Google Scholar 

  • Bägli DJ, Steele jr GD, Barlozzari T (1989) Natural killer sensitivity of colorectal carcinoma targets. Arch Surg 124:89–93

    Google Scholar 

  • Balch CM, Tilden AB, Dougherty PA, Cloud GA, Abo T (1983) Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients. Ann Surg 198:192–199

    Google Scholar 

  • Balch CM, Tilden AB, Dougherty PA, Cloud GA, Abo T (1984) Heterogeneity of natural killer lymphocyte abnormalities in colon cancer patients. Surgery 95:63–70

    Google Scholar 

  • Basham T, Merigan TC (1982) Immunoregulation by gamma-interferon? Nature 299:778–782

    Google Scholar 

  • Beaupain R, Billard C, Falcoff E (1986) Effects of human recombinant interferon-alpha 2, beta and gamma on growth and survival of human cancer nodules maintained in continuous organotypic culture. Eur J Cancer Clin Oncol 22:141–149

    Google Scholar 

  • Billiau A (1981) The clinical value of interferons as antitumor agents. Eur J Cancer Clin Oncol 17:949

    Google Scholar 

  • Cantrell JE Jr, Hart RD, Taylor RF, Harvey JH Jr (1987) Pilot trial of prolonged continuous-infusion 5-fluorouracil and weekly cisplatin in advanced colorectal cancer. Cancer Treat Rep 71:615–618

    Google Scholar 

  • Clark DA, McCulloch PB, Liao SK, Dent PB, Fuks A (1984) Sensitivity of human carcinoma cell lines to lysis by blood natural killer cells correlating with surface expression of carcinoembryonic antigen. JNCI 72:505–512

    Google Scholar 

  • Clercq E de, Zhang ZX, Huygen K (1982) Synergism in the antitumor effects of type 1 and type II interferon in mice inoculated with leukemia L1210 cells. Cancer Lett 15:223–228

    Google Scholar 

  • Czarniecki CW, Fennie C, Powers DB, Estell DA (1984) Synergistic antiviral and antiproliferative activities ofEscherichia coli-derived human alpha, beta, and gamma interferons. J Virol 49:490–496

    Google Scholar 

  • Ebert EC, Roberts Al, O'Connell SM, Robertson FM, Nagase H (1987) Characterization of an immunosuppressive factor derived from colon cancer cells. J Immunol 138:2161–2168

    Google Scholar 

  • Elias L, Crissmann HA (1988) Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res. 48:4868–4873

    Google Scholar 

  • Fleischmann WR Jr (1982) Potentiation of the direct anticellular activity of mouse interferons: mutual synergism and interferon concentration dependence. Cancer Res 42:869–875

    Google Scholar 

  • Guillou PJ, Sedman PC, Ramsden CW (1989) Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro. Cancer Immunol Immunother 28:43–53

    Google Scholar 

  • Hamied TAA, Parker D, Turk JL (1986) Potentiation of release of interleukin-2 by bleomycin. Immunopharmacology 12:127–134

    Google Scholar 

  • Hilgard P, Pohl J, Stekar J, Voegeli R (1985) Oxazaphosphorines as biological response modifiers — experimental and clinical perspectives. Cancer Treat Rev 12:155–162

    Google Scholar 

  • Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, Reibnegger G, Swetly P, Troppmair J, Wachter H (1984) Immune response-associated production of neopterin. Release from macrophages primarily under control of interferongamma. J Exp Med 160:310–316

    Google Scholar 

  • Huberman M, Bering H, Tessitore J, Groopman J, Tran L, Young D, Evans L (1990) 5-fluorouracil (5FU) plus recombinant alpha interferon (ROFERON A) in advanced colorectal cancer (abstract). Proc Am Soc Clin Oncol 9:116

    Google Scholar 

  • Kemeny N, Kelsen D, Derby S, Sammarco P, Adams L, Murray P, (1990) Combination 5-fluorouracil (FU) and recombinant alpha-interferon (ifn) in advanced colorectal carcinoma: activity but significant toxicity (abstract). Proc Am Soc Clin Oncol 9:109

    Google Scholar 

  • Klein HO (1988) Untersuchungen zur Immuntherapie des metastasierenden Hypernephroms und anderer solider Tumoren. Aktuel Immunol 6:13–29

    Google Scholar 

  • Klein HO, Kreysch HG, Coerper C, Voigt P, Ruff I (1987) Preclinical and early clinical trial with mafosfamide as immune modulator. Methods Find Exp Clin Pharmacol 9:627–640

    Google Scholar 

  • Kondo H, Tanaka N, Naomoto Y, Orita K (1987) Antitumor effect of recombinant human interferon-beta and interferon-gamma in combination against human colon cancer cell line in vitro and in nude mice. Jpn J Cancer Res (Gann) 78:1258–1265

    Google Scholar 

  • Krim M (1980) Towards tumor therapy with interferons: part I. Interferons: production and properties. Blood 55:711

    Google Scholar 

  • Krown SE, Mintzer D, Cunningham-Rundles S, Niedzwieki D, Krim M, Einzig AI, Gabrilove JL, Shurgot B, Gessula J (1987) High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses. Cancer Treat Rep 71:39–45

    Google Scholar 

  • Le J, Yip YK, Vilcek J (1984) Cytolytic activity of interferongamma and its synergism with 5-fluorouracil. Int J Cancer 34:495–500

    Google Scholar 

  • Lillis PK, Brown TD, Beougher K, Koeller J, Marcus SG, Von Hoff DD (1987) Phase II trial of recombinant beta interferon in advanced colorectal cancer. Cancer Treat Rep 71:965–967

    Google Scholar 

  • Marx JL (1979a) Interferon (I): on the threshold of clinical application. Science 204:1183

    Google Scholar 

  • Marx JL (1979a) Interferon (I): on the threshold of clinical applica. Science 204:1293

    Google Scholar 

  • Matsunaga H, Kuwahara Y, Kusugami K, Morise K, Shimokata K (1988) Natural killer, lymphokine-activated killer and interferon-gamma producing activities of peripheral blood-and regional lymph node mononuclear cells in 23 cases of colorectal cancer. Gastroenterol 23:527–533

    Google Scholar 

  • Miescher S, Whiteside TL, Carrell S, Fliedner V von (1986) Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 136:1899–1907

    Google Scholar 

  • Miyoshi T, Ogawa S, Kanamori T, Nobuhara M, Namba M (1983) Interferon potentiates cytotoxic effects of 5-fluorouracil on cell proliferation of established human cell lines originating from neoplastic tissues. Cancer Lett 17:239–247

    Google Scholar 

  • Monson JRT, Ramsden C, Guillou PJ (1986) Decreased interleukin-2 production in patients with gastrointestinal cancer. Br J Surg 73:483–486

    Google Scholar 

  • Namba M, Miyoshi T, Kanamori T, Nobuhara M, Kimoto T, Ogawa S (1982) Combined effects of 5-fluorouracil and interferon on proliferation of human neoplastic cells in culture. Gann 73:819–824

    Google Scholar 

  • Namba M, Yamamoto S, Tanaka H, Kanamori T, Nobuhara M, Kimoto T (1984) In vitro and in vivo studies on potentiation of cytotoxic effects of anticancer drugs or cobalt 60 gamma ray by interferon on human neoplastic cells. Cancer 54:2262–2267

    Google Scholar 

  • Niederle N, Kurschel E, Schmidt CG (1984) Biologischer Effekt von rekombiniertem Leukozyten-alpha 2-Interferon bei metastasierten kolorektalen Karzinomen. Dtsch Med Wochenschr 109:779–782

    Google Scholar 

  • O'Connell MJ, Ritts RA Jr, Moertel CG, Schutt AJ, Sherwin SA (1989) Recombinant interferon-gamma lacks activity against metastatic colorectal cancer but increases serum levels of CA 199. Cancer 63:1998–2004

    Google Scholar 

  • Oleszak E, Stewart WE (1985) Potentiation of the antiviral and anticellular acitivities of interferons by mixtures of HulFN-gamma and HulFN-alpha or HuIFN-beta. J Interferon Res 5:361–371

    Google Scholar 

  • Parker D, Turk JL (1984) Potentiation of T-lymphocyte function by bleomycin. Immunopharmacology 7:109–113

    Google Scholar 

  • Pinedo HM, Chabner BA (eds) (1987–1989) Cancer chemotherapy. The EORTC cancer chemotherapy annuals. Elsevier, Amsterdam

    Google Scholar 

  • Pommier GJ, Garrouste FL, Bettetini D, Culouscou M, Remacle-Bonnet MM (1987) In vivo delayed rejection of tumors and inhibition of delayed-type hypersensitivity by HT-29 human colonic adenocarcinoma cell line. Cancer Immunol Immunother 24:225–230

    Google Scholar 

  • Rosenberg SA (1988) Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today 9:58–62

    Google Scholar 

  • Schabel FM Jr, Trader MW, Laster WT Jr, Corbett TH, Griswold DP Jr (1979) Cis-dichlorodiammineplatinum (II): combination chemotherapy and crossresistance studies with tumors of mice. Cancer Treat Rep 63:1459–1473

    Google Scholar 

  • Scheithauer W (1989) Palliative Chemotherapie und Immuntherapie des kolorektalen Karzinoms. Tumor Diagnostik Ther 10:1–12

    Google Scholar 

  • Schiller JH, Groveman DS, Schmid SM, Willson JKV, Cummings KB, Borden EC (1986) Synergistic antiproliferative effects of human recombinant alpha54-or beta-interferon with gamma-interferon on human cell lines of various histogenesis. Cancer Res 46:483–488

    Google Scholar 

  • Trave F, Rustum YM, Goranson J (1985) Synergistic antitumor activity ofcis-platin (DDP) and 5-fluorouracil (FUra) in mice bearing leukemia L1210 cells (abstract). Proc Am Assoc Cancer Res 26:322

    Google Scholar 

  • Triozzi PL, Kenney P, Young D, Rinehart JJ (1987) Open-label phase II trial of recombinant beta interferon (IFN-beta) in patients with colorectal cancer. Cancer Treat Rep 71:983–984

    Google Scholar 

  • Vilcek J, Gray PW, Rinderknecht E, Sevastopoulos CG (1984) Interferon gamma: a lymphokine for all seasons. In: Pick E (ed) Lymphokines, vol, 12. Academic Press, Orlando, Fla.

    Google Scholar 

  • Wadler S, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmerman M, Itri L, Weinberg V, Wiernik PH (1989) Fluorouracil and recombinant alpha-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 7:1769–1775

    Google Scholar 

  • Wanebo HJ (1983) Host immunologic impairment in relation to survival. In: Stoll BA (ed) Cancer treatment: end-point evaluation. New horizons in oncology, vol 2. Wiley, Chichester, pp 209–250

    Google Scholar 

  • Weigent DA, Langford MP, Fleischmann WR Jr, Stanton GJ (1983) Potentiation of lymphocyte natural killing by mixtures of alpha or beta interferon with recombinant gamma interferon. Infect Immun 40:35–38

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Clinic I, University of Cologne, Cologne, Federal Republic of Germany

    H. O. Klein, G. Golbach, P. Voigt, C. Coerper & C. Bernhardt

Authors
  1. H. O. Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Golbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Voigt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Coerper
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Bernhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klein, H.O., Golbach, G., Voigt, P. et al. Combination of interferons and cytostatic drugs for treatment of advanced colorectal cancer. J Cancer Res Clin Oncol 117 (Suppl 4), S214–S220 (1991). https://doi.org/10.1007/BF01613230

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01613230

Key words

Search

Navigation